TITLE:
Association of Basedow’s Disease and Comorbidities at the Abass Ndao Hospital Center (Senegal)
AUTHORS:
Papa Gallo Sow, Djiby Sow, Hamsatou Diouf, Louis Diaga Diouf, Aboubakry Dramé, Gora M’baye
KEYWORDS:
Epidemiology, Basedow, Comorbidities, Senegal
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.12 No.12,
December
6,
2024
ABSTRACT: Introduction: Graves’ disease associated with comorbidities can increase morbidity and mortality. Our objective was to describe the epidemiological, clinical, therapeutic and evolutionary aspects of comorbidities associated with Graves’ disease at the Abass hospital center, Ndao. Methods: This was a cross-sectional and descriptive study conducted from January 2020 to December 2020. It focused on patients followed for Graves’ disease at Abass hospital, Ndao de Dakar. Epidemiological, clinical, therapeutic and evolutionary data were evaluated. Results: Three hundred and three eighteen (318) cases were collected, 70 of which had comorbidities (51.15%). The average age was 38.45 years with extremes ranging from 15 to 71 years. Women represented 91.42% of patients. A consultation delay of more than one year was noted in 24.29%. Cardiovascular comorbidities were dominated by hypertension with 30%. Graves’ disease was associated with an evolving pregnancy in 10 women. Endocrine comorbidities were dominated by type 1 diabetes noted in 8.57% each. Biermer’s disease was noted in 2 patients. Female gender was the most common etiological factor of Graves’ disease noted in 64 patients (91.42%). A hereditary predisposition existed in 4 patients (5.71%), stress was noted in 7 patients (10%). 43 patients were under thyrozol (61.42%), 41 patients were on propranolol (58.57%), 14 patients were on carbimazole (20%). A good balance was noted in 44 cases (68.75%) after 9 months of treatment. Conclusion: Graves’ disease is a public health problem with nonspecific signs. It requires screening and treating comorbidities to reduce morbidity and mortality.